Willow vs Zealthy: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent researchHow we rank →

Willow beats Zealthy overall, scoring 8.2/10 vs 7.2/10. Zealthy is more affordable at $286/mo vs $299/mo. Choose Willow for users who want comprehensive clinical support with flexibili. Choose Zealthy for users who want the option to switch between compounded and b.

A side-by-side comparison of Willow and Zealthy covering pricing, scores, medication types, insurance, and more to help you decide.

Higher Rated

Willow

#8 of 48
8.2/10

Personalized GLP-1 weight loss with ongoing clinical support. Compounded semaglutide and tirzepatide only — Willow explicitly does not prescribe brand-name Wegovy or Zepbound. Added oral compounded semaglutide tablets as a non-injectable option.

Visit Willow

Zealthy

#42 of 48
7.2/10

Flexible GLP-1 provider allowing patients to switch between compounded and brand-name medications as needed.

Visit Zealthy
FeatureWillowZealthy
Our Score8.2/107.2/10
Starting Price$299/mo$286/mo
Medication TypeCompoundedBoth
Insurance AcceptedNoNo
Best ForUsers who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routesUsers who want the option to switch between compounded and brand-name GLP-1s
Ranking#8#42

Pros & Cons Compared

Willow

Pros

  • +Includes monthly provider check-ins and dose adjustments at no extra cost
  • +Offers both injectable AND oral compounded semaglutide — one of few platforms with a daily oral tablet option
  • +$299/mo all-in for compounded semaglutide with monthly provider support
  • +90%+ patient retention rate after 3 months per their published outcomes data

Cons

  • Compounded-only — no brand-name Wegovy or Zepbound through the platform
  • Tirzepatide pricing reaches $499-$524 at higher doses — starting dose is $399/mo
  • Cash-pay only — no insurance billing, though they provide superbills for FSA/HSA
  • Founded in 2024 — less track record than Ro or Hims, though growth has been fast

Zealthy

Pros

  • +Dedicated insurance coordinators handle prior authorizations — potentially bringing brand-name GLP-1 costs to $25/mo
  • +Multi-month supply options (3, 6, or 12 months) — unique convenience most monthly-shipping competitors can't match
  • +Both compounded and brand-name (Wegovy, Zepbound) available with clinician-guided selection
  • +LegitScript certified with 4.5-star Review.io rating

Cons

  • $135 membership fee on top of medication cost makes cash-pay total ~$286/mo for semaglutide — above average
  • Young company (founded 2023) with a relatively small review base — less track record than established platforms
  • Prescription products are non-refundable for any reason once ordered

Our Verdict

Willow edges out Zealthy with a score of 8.2/10 vs 7.2/10. If budget is your priority, Zealthy starts at $286/mo compared to Willow's $299/mo. Zealthy offers both brand-name and compounded medications, giving you more flexibility. Choose Willow if you want: users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes. Choose Zealthy if you want: users who want the option to switch between compounded and brand-name glp-1s.

Still undecided? Editor's #1 Overall Pick

Eden Health GLP-1

$249/mo · 8.9/10 · Both

If neither Willow nor Zealthy feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Eden Health GLP-1 — strongest balance of clinical oversight, transparent pricing, and verified availability.

Try Willow

Starting at $299/mo

Visit Willow

Try Zealthy

Starting at $286/mo

Visit Zealthy

Related comparisons

Other matchups readers comparing Willow or Zealthy tend to look at next.

Top Picks

Four programs our readers click through most.

Eden Health GLP-1

8.9/10
$249/mo·Brand & Compounded

Embody

7.3/10
$299/mo·Compounded

Gala

7.2/10
$149/mo·Brand & Compounded

Affiliate links — we earn a commission at no extra cost to you. Selection reflects what readers convert through, not editorial endorsement. Full ranking + methodology at glp1picks.com.